NIPH Clinical Trials Search

JAPANESE
国立保健医療科学院
UMIN ID: C000000254

Registered date:01/10/2005

Japan Erythropoietin Treatment Study for Target Hb and Survival

Basic Information

Recruitment status Complete: follow-up complete
Health condition(s) or Problem(s) studiedRenal anemia under hemodialysis
Date of first enrollment2005/10/01
Target sample size10000
Countries of recruitmentJapan
Study typeObservational
Intervention(s)

Outcome(s)

Primary OutcomeThe relationship between maintenance Hb and vital prognosis (survival) at six months after the start of Epogin® Injection administration is investigated, and the optimal target Hb is established with respect to vital prognosis.
Secondary Outcome(1) As with vital prognosis (survival), the optimal target Hb is investigated in relation to hospitalization. However, hospitalization due to testing or social purposes is excluded. (2) The effects of erythropoietin therapy during the maintenance phase on vital prognosis and hospitalization following the initiation of dialysis are investigated.

Key inclusion & exclusion criteria

Age minimumNot applicable
Age maximumNot applicable
GenderMale and Female
Include criteria
Exclude criteria1) Patients undergoing other types of dialysis – e.g., CAPD, HDF, or HF 2) Patients undergoing hemodialysis and another type of dialysis simultaneously 3) Patients who have undergone other types of dialysis prior to hemodialysis 4) Patients in whom dialysis has been terminated, then resumed 5) Patients who have received another erythropoietin preparation after initiation of hemodialysis 6) Patients who do not give informed consent

Related Information

Contact

public contact
Name SHIGERU NIHOJIMA
Address 1-1 Muromachi 2 Cho-me, Nihonbashi, Chuou-Ku, Tokyo, #103-8324, JAPAN Japan
Telephone 03-3273-0773
E-mail nihojimasgr@chugai-pharm.co.jp
Affiliation CHUGAI PHARMACEUTICAL CO.LTD. PHARMACOVIGILANCE Dept.
scientific contact
Name SYUNJI YOKOYAMA
Address 1-1 Muromachi 2 Cho-me, Nihonbashi, Chuou-Ku, Tokyo, #103-8324, JAPAN Japan
Telephone 03-3273-0773
E-mail
Affiliation CHUGAI PHARMACEUTICAL CO.LTD. Drug Safety Unit